FinTrust Capital Advisors’s Serina Therapeutics SER Stock Holding History

FinTrust Capital Advisors’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2	Closed	–	–	1190
2019 Q4	$0	Buy	+2	New	+$108	﹤0.01%	1130

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

FinTrust Capital Advisors's SER Position: Q1 2020 in Review

FinTrust Capital Advisors sold out of Serina Therapeutics (SER) in Q1 2020, closing a stake of 2 shares.

FinTrust Capital Advisors first reported a position in SER in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 49 funds tracked by Wall St. Rank hold SER as of Q1 2020.

FinTrust Capital Advisors reported no remaining Serina Therapeutics position as of Q1 2020 after selling out during the quarter.
FinTrust Capital Advisors sold 2 Serina Therapeutics shares in Q1 2020.
FinTrust Capital Advisors first reported a position in Serina Therapeutics in Q4 2019 and held it in 1 quarter.
FinTrust Capital Advisors's Serina Therapeutics position peaked at $0 in Q4 2019.
49 funds tracked by Wall St. Rank held Serina Therapeutics as of Q1 2020.

Based on FinTrust Capital Advisors's 13F filing for Q1 2020, filed 15 May 2020.